Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer Issues Earnings Nov. 25; Update Expected On Strategic Realignment

This article was originally published in The Pink Sheet Daily

Executive Summary

Company’s plans to expand its U.S. oncology business and its recent deal with Schering-Plough for primary care product marketing rights in the U.S. are likely to be a focus of discussion. Bayer’s shareholders approve spin-off of Lanxess chemicals/polymers unit.

You may also be interested in...

Schering-Plough Adds Levitra To Product Portfolio Through Deal With Bayer

Bayer abandons primary care market in U.S. and will cut 1,800 sales positions. Schering-Plough will take over marketing of Avelox and Cipro as well as Bayer's portion of Levitra co-promotion efforts.

"Bayer-ly" An Rx Company? Viadur Is Focus Of New Bayer Oncology Unit

Bayer is setting up a new oncology division in West Haven, Conn. as the focus of its U.S. prescription drug business following a Sept. 13 licensing deal with Schering-Plough

Editor's Note: Please Help Pink Sheet Serve You Best

Please take our brief reader survey to help us better understand your content and delivery needs.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts